Alnylam Pharmaceuticals | ALNY - Equity Capital And Reserves


Alnylam Pharmaceuticals reported $1.08B in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 1.25B 20.68M Mar/2026
Agios Pharmaceuticals USD 1.11B 84M Mar/2026
Alnylam Pharmaceuticals USD 1.08B 286.2M Mar/2026
Amgen USD 9.19B 532M Mar/2026
Arrowhead Research USD 613.98M 45.56M Mar/2026
BioCryst Pharmaceuticals USD -553.84M 434.69M Mar/2026
BioMarin Pharmaceutical USD 6.21B 125.11M Mar/2026
Incyte USD 5.62B 455.37M Mar/2026
Ionis Pharmaceuticals USD 491.41M 2.32M Mar/2026
Moderna USD 7.41B 1.24B Mar/2026
Neurocrine Biosciences USD 3.41B 154.3M Mar/2026
Novartis USD 46.13B 1.8B Dec/2025
PTC Therapeutics USD -180.46M 24.85M Mar/2026
Regeneron Pharmaceuticals USD 31.42B 166.7M Mar/2026
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Sanofi EUR 71.71B 14.25B Dec/2025
Sarepta Therapeutics USD 1.51B 364.48M Mar/2026
Takeda JPY 7.77T 129.5B Mar/2026
Tectonic Therapeutic USD 230.42M 20.91M Mar/2026
Ultragenyx Pharmaceutical USD -236M 156M Mar/2026
Vertex Pharmaceuticals USD 19.36B 696.1M Mar/2026
Xencor USD 515.63M 119.95M Mar/2026